The global spinal cord stimulation industry is anticipated to grow until 2028, according to WhaTech.
Here are five insights:
1. As chronic pain cases continue to grow, so will the SCS market.
2. A growing adult population, rising demand for minimally invasive surgery and increasing technological advancements will spur market growth in the United States.
3. Costliness, strict regulations and reliance on traditional SCS therapy will hinder global market growth.
4. The SCS market has concentrated competition, with a few dominant companies.
5. Medtronic, Nevro, Boston Scientific and St. Jude Medical lead the market.